Article

Lifetime Risk of RA Higher Than Previously Thought

The lifetime risk of inflammatory autoimmune rheumatologic disease is substantial-1 in 12 for women and 1 in 20 for men, and the lifetime risk of rheumatoid arthritis (RA)-1 in 28 for women and 1 in 59 for men-is higher than previously thought.

The lifetime risk of inflammatory autoimmune rheumatologic disease is substantial-1 in 12 for women and 1 in 20 for men, and the lifetime risk of rheumatoid arthritis (RA)-1 in 28 for women and 1 in 59 for men-is higher than previously thought. However, the risks are smaller than those for diseases considered to be common.

Crowson and associates reviewed population-based data from 1179 patients with RA and smaller numbers of patients with systemic lupus erythematosus (SLE), psoriatic arthritis (PsA), polymyalgia rheumatica (PMR), giant cell arteritis (GCA), ankylosing spondylitis (AS), and Sjgren syndrome (SS). They integrated the data with mortality rates from life tables from the US population to estimate gender-specific lifetime risks.

RA is the most common inflammatory autoimmune rheumatologic disease, with lifetime risks of 3.6% and 1.7% for women and men, respectively, followed by PMR, with risks of 2.4% and 1.7%. The lifetime risks in other diseases for women and men, respectively, were GCA, 1.0% and 0.5%; SLE, 0.9% and 0.2%; PsA, 0.5% and 0.6%; SS, 0.75% and 0.04%; and AS, 0.08% and 0.63%.

The authors noted that this information may help physicians counsel patients and promote awareness of this group of diseases, ultimately improving management.

 

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.